$OCGN News

Canaccord Genuity Maintains Buy on Ocugen, Lowers Price Target to $11

Ocugen, Inc. (OCGN) Q1 2026 Earnings Call Transcript

Ocugen (NASDAQ:OCGN) Beats Q1 Revenue Estimates but Widens Net Loss, Announces $115M Capital Raise to Fund Pipeline Through 2028

Full Transcript: Ocugen Q1 2026 Earnings Call

Ocugen Q1 EPS $(0.06) Misses $(0.05) Estimate, Sales $1.533M Beat $540.000K Estimate

Ocugen Plans To Commence $115M Senior Notes Offering

Ocugen Completes Dosing In Phase 2/3 GARDian3 Trial Of OCU410ST For Stargardt Disease Ahead Of Schedule Topline Data Expected In 2Q27

HC Wainwright & Co. Maintains Buy on Ocugen, Raises Price Target to $10

Ocugen, Inc. (OCGN) Discusses Top Line Results From Phase II ArMaDa Trial of OCU410 in Geographic Atrophy Transcript

Ocugen shares are trading lower after the company announced topline 12-month data from its Phase 2 ArMaDa clinical trial evaluating OCU410 for geographic atrophy secondary to dry age-related macular degeneration. Key findings include a 31% reduction in lesion growth in the optimal dose group compared to control.

Ocugen's 12-month Data From Phase 2 ArMaDa trial of OCU410 (AAV5-RORA) For Geographic Atrophy Secondary To Dry Age-related Macular Degeneration Demonstrates Statistically Significant Reduction In Lesion Growth

Ocugen shares are trading higher after the company announced that it will host a conference call and webcast to discuss the full data set from the Phase 2 ArMaDa clinical trial evaluating OCU410 for geographic atrophy, late-stage dry age-related macular degeneration.

Ocugen To Present Full Phase 2 ArMaDa Data For OCU410 Gene-Agnostic Modifier Gene Therapy For Geographic Atrophy In March 24 Webcast

Ocugen shares are trading higher after Canaccord Genuity initiated coverage on the stock with a Buy rating and announced a $12 price target.

Canaccord Genuity Initiates Coverage On Ocugen with Buy Rating, Announces Price Target of $12

Why Is Ocugen Stock Soaring Today?

Ocugen shares are trading higher after Oppenheimer initiated its coverage on the stock with an Outperform rating and announced a price target of $10.

Oppenheimer Initiates Coverage On Ocugen with Outperform Rating, Announces Price Target of $10

Ocugen: Downgrading After OCU410 Data Release

Ocugen Inc (NASDAQ:OCGN) Stock Drops 7% on Q4 Revenue Miss, Highlights Clinical Pipeline